U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07497594) titled 'ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention' on March 03.
Brief Summary: The goal of this study is to learn how well long-acting lenacapavir works to prevent human immunodeficiency virus (HIV) infection in people at higher risk of getting HIV in Brazil. The study will also learn about safety, continued use over time, and whether people prefer this option compared to daily oral pre- exposure prophylaxis (PrEP). The main questions it aims to answer are:
How many participants get HIV while using long-acting lenacapavir? How safe is long-acting lenacapavir in real-world health services? How many participants continu...